ResearcherFondazione IRCCS Istituto Nazionale dei TumoriActive in the last 2 years

Giuseppe Leoncini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3965-7635; OpenAlex author ID A5041373409, A5091162798. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 3

Aquaporin-1 differentiates intrahepatic cholangiocarcinoma from liver metastases of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/his.70108 ↗
Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2025.102208 ↗
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. Co-author DOI 10.1002/cam4.70393 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Vincenzo Mazzaferro · 3 shared papers, 2024–2026 · strength 0.69
Davide Citterio · 1 shared paper, 2025 · strength 0.23
- Paper Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. DOI 10.1016/j.suronc.2025.102208 ↗
Andrea Zironda · 1 shared paper, 2025 · strength 0.23
- Paper Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. DOI 10.1016/j.suronc.2025.102208 ↗
Michele Mazzola · 1 shared paper, 2025 · strength 0.23
- Paper Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. DOI 10.1016/j.suronc.2025.102208 ↗
Giovanni Carlo Ferrari · 1 shared paper, 2025 · strength 0.23
- Paper Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. DOI 10.1016/j.suronc.2025.102208 ↗
Samuele Grandi · 1 shared paper, 2025 · strength 0.23
- Paper Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. DOI 10.1016/j.suronc.2025.102208 ↗
Federico Nichetti · 1 shared paper, 2024 · strength 0.15
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393 ↗
Sara Pusceddu · 1 shared paper, 2024 · strength 0.15
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393 ↗
Federica Perrone · 1 shared paper, 2024 · strength 0.15
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393 ↗
Monica Niger · 1 shared paper, 2024 · strength 0.15
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.